[Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares April 12, 2019 05:04 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an updat]
[Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares April 12, 2019 05:04 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an updat]
[CUSIP No. P8696W104 1. Names of Reporting Persons 1Globe Capital LLC 80-0841812 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5.]
[CUSIP No. P8696W104 1. Names of Reporting Persons 1Globe Capital LLC 80-0841812 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5.]
[Sinovac: Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares March 8, 2019 BEIJING, – Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common ]
[Sinovac: Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares March 8, 2019 BEIJING, – Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common ]
[Sinovac: Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares March 8, 2019 BEIJING, – Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common ]
[Sinovac: Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares March 8, 2019 BEIJING, – Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common ]
[Sinovac Determines Trigger Event Occurred Under Rights Agreement · Sinovac Board of Directors Determines Certain Collaborating Shareholders Became Acquiring Persons, Voiding their Preferred Share Purchase Rights; · Valid Preferred Share Purchase Rights Held by all Non-Collaborating Shareholders Exch]
[Sinovac Determines Trigger Event Occurred Under Rights Agreement · Sinovac Board of Directors Determines Certain Collaborating Shareholders Became Acquiring Persons, Voiding their Preferred Share Purchase Rights; · Valid Preferred Share Purchase Rights Held by all Non-Collaborating Shareholders Exch]
